Oslo, 5 May 2017
In accordance with the authorisation granted by the Annual General Meeting 19 May 2016, the Board of Directors of PCI Biotech Holding ASA has awarded a total of 340,000 share options to key employees. Each share option gives the right to subscribe for or acquire one share per option (after PCI Biotech Holding ASA's choice), at a strike price of NOK 24.95, equal to the volume weighted average share price (VWAP) for the last 5 days of trade prior to the grant date. The options can be exercised with 1/3 of the options after one year, further 1/3 after two years and the last third after three years. The share options are lapsing in Q3 2022.
Of these share options, 95,000 share options were allotted to Per Walday, CEO. After the allocation, Per Walday holds a total portfolio of 120,000 unexercised share options and 63,561 shares.
60,000 share options were allotted to Anders Høgset, CSO. After the allocation, Anders Høgset holds a total portfolio of 77,000 unexercised share options and 61,375 shares.
50,000 share options were allotted to Ronny Skuggedal, CFO. After the allocation, Ronny Skuggedal holds a total portfolio of 116,000 unexercised share options and 25,066 shares.
20,000 share options were allotted to Kristin Eivindvik, PD. After the allocation, Kristin Eivindvik holds a total portfolio of 44,500 unexercised share options and 16,867 shares.
15,000 share options were allotted to Gaël L'Hévéder, CBDO. After the allocation, Gaël L'Hévéder holds a total portfolio of 106,000 unexercised share options and 10,000 shares.
The current authorisation, as of 19 may 2016, allows for a total of 745,000 share options, of which 735,000 now have been granted by the Board of Directors.
For more information, please contact:
Per Walday, CEO, pw@pcibiotech.no, Mobile: +47 917 93 429